Tangent Medical Announces U.S. Launch of the NovaCath Integrated IV Catheter System
Healthcare Facilities Begin Evaluations On Next-Generation IV Catheter System
Tangent Medical, an innovator in IV therapy products and creator of the NovaCath Integrated IV Catheter System, announced today its commercial product launch and start to clinical evaluations in several healthcare facilities across the U.S. The commercialization of this product is the first significant advancement in the IV catheter market in more than a decade.
“The NovaCath Integrated IV Catheter System was developed after a year of clinical immersion to address many patient and clinician needs, while providing benefits to healthcare facilities and hospitals in the area of compliance and economics,” said Tangent Medical CEO Jeff Williams. “The anticipated launch of the NovaCath has resulted in significant clinical interest and demand for the product. We are excited about the opportunity to work with healthcare facilities in the evaluation and adoption of this new technology, and commend our team for its ability to rapidly move the NovaCath from concept to commercialization.”
NovaCath is the first safety IV catheter offering advanced catheter stabilization technology designed to exceed the highest CDC, OSHA and INS standards for IV catheter stabilization. Its passive needle shielding technology and closed system design minimizes occupational exposure to blood to the lowest feasible extent. Several patented design features uniquely position NovaCath to offer healthcare facilities uncompromising safety and satisfaction – both to the clinician and the patient. NovaCath’s ergonomic design and soft materials will improve patient comfort and minimize the risk of pressure ulcers that can result from use of traditional catheters. In addition, its 180-degree fluid-path turn eliminates the J-Loop, which can cause IV tubing snags and catheter dislodgement. NovaCath’s pre-assembled, all-in-one system minimizes IV catheter set-up time and risk of touch-point contamination.
“Clinical feedback supports NovaCath’s ability to reduce overall IV complications while improving clinical efficiency and healthcare worker safety,” said Curtis Bloch, Vice President of Sales & Marketing for Tangent Medical. ‘’Being recognized as one of 14 innovations at the Premier’s 2013 Breakthrough Conference and Exhibition last week was a major industry validation of the impact we will have on advancing IV therapy and improving patient satisfaction. No other catheter on the market combines advanced stabilization, passive needle encapsulation, tubing management and blood control on every single start.”